Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Total Debt (2023 - 2025)

Historic Total Debt for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $677438.4.

  • Zhengye Biotechnology Holding's Total Debt changed N/A to $677438.4 in Q2 2025 from the same period last year, while for Jun 2025 it was $677438.4, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2024, which is 8687.55% down from last year.
  • According to the latest figures from Q2 2025, Zhengye Biotechnology Holding's Total Debt is $677438.4.
  • Zhengye Biotechnology Holding's 5-year Total Debt high stood at $12.5 million for Q4 2023, and its period low was $677438.4 during Q2 2025.
  • For the 3-year period, Zhengye Biotechnology Holding's Total Debt averaged around $4.9 million, with its median value being $1.7 million (2024).
  • Data for Zhengye Biotechnology Holding's Total Debt shows a peak YoY increase of 8662.4% (in 2024) and a maximum YoY decrease of 8662.4% (in 2024) over the last 5 years.
  • Over the past 3 years, Zhengye Biotechnology Holding's Total Debt (Quarter) stood at $12.5 million in 2023, then plummeted by 86.62% to $1.7 million in 2024, then tumbled by 59.42% to $677438.4 in 2025.
  • Its last three reported values are $677438.4 in Q2 2025, $1.7 million for Q4 2024, and $12.5 million during Q4 2023.